Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.43
TRNX's Cash to Debt is ranked lower than
79% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.24 vs. TRNX: 0.43 )
Ranked among companies with meaningful Cash to Debt only.
TRNX' s Cash to Debt Range Over the Past 10 Years
Min: 0.18  Med: 0.81 Max: N/A
Current: 0.43
Equity to Asset 0.38
TRNX's Equity to Asset is ranked lower than
83% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. TRNX: 0.38 )
Ranked among companies with meaningful Equity to Asset only.
TRNX' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.71 Max: 0.79
Current: 0.38
0.31
0.79
F-Score: 2
Z-Score: 0.45
M-Score: -2.49
WACC vs ROIC
5.91%
-22.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -40.79
TRNX's Operating margin (%) is ranked lower than
72% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. TRNX: -40.79 )
Ranked among companies with meaningful Operating margin (%) only.
TRNX' s Operating margin (%) Range Over the Past 10 Years
Min: -116.46  Med: -14.25 Max: -2.74
Current: -40.79
-116.46
-2.74
Net-margin (%) -94.24
TRNX's Net-margin (%) is ranked lower than
79% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.43 vs. TRNX: -94.24 )
Ranked among companies with meaningful Net-margin (%) only.
TRNX' s Net-margin (%) Range Over the Past 10 Years
Min: -113.05  Med: -22.86 Max: -7.84
Current: -94.24
-113.05
-7.84
ROE (%) -73.73
TRNX's ROE (%) is ranked lower than
85% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. TRNX: -73.73 )
Ranked among companies with meaningful ROE (%) only.
TRNX' s ROE (%) Range Over the Past 10 Years
Min: -73.73  Med: -20.18 Max: -5.19
Current: -73.73
-73.73
-5.19
ROA (%) -37.06
TRNX's ROA (%) is ranked lower than
76% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: -0.39 vs. TRNX: -37.06 )
Ranked among companies with meaningful ROA (%) only.
TRNX' s ROA (%) Range Over the Past 10 Years
Min: -40.3  Med: -9.33 Max: -3.73
Current: -37.06
-40.3
-3.73
ROC (Joel Greenblatt) (%) -76.59
TRNX's ROC (Joel Greenblatt) (%) is ranked lower than
67% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 4.23 vs. TRNX: -76.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TRNX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -197.56  Med: -32.58 Max: -18
Current: -76.59
-197.56
-18
Revenue Growth (3Y)(%) -2.50
TRNX's Revenue Growth (3Y)(%) is ranked lower than
69% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. TRNX: -2.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TRNX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -14.9  Med: -5.3 Max: -2.5
Current: -2.5
-14.9
-2.5
EPS Growth (3Y)(%) 89.60
TRNX's EPS Growth (3Y)(%) is ranked higher than
92% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. TRNX: 89.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TRNX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -38.1  Med: 60 Max: 89.6
Current: 89.6
-38.1
89.6
» TRNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2015

TRNX Guru Trades in Q1 2015

Steven Cohen 190,400 sh (-4.61%)
» More
Q2 2015

TRNX Guru Trades in Q2 2015

Steven Cohen 36,000 sh (-81.09%)
» More
Q3 2015

TRNX Guru Trades in Q3 2015

Steven Cohen 415,700 sh (+1054.72%)
» More
Q4 2015

TRNX Guru Trades in Q4 2015

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TRNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:HTWR, OTCPK:BSNRY, NAS:SPNC, NAS:LDRH, NAS:CNMD, NAS:INGN, OTCPK:DGWPF, NAS:VASC, NAS:MDXG, NAS:OFIX, NAS:CYNO, NAS:BABY, NAS:CSII, NAS:KTWO, OTCPK:IOBCF, NYSE:ITGR, OTCPK:SBMAF, OTCPK:NISOF, NAS:ZLTQ, NYSE:CRY » details
Traded in other countries:T98.Germany,
Wright Medical Group NV a medical device company, designs, manufactures, markets, and sells orthopaedic products in the United States, France, and internationally. It offers joint implants & bone fixation devices for the shoulder, elbow, foot, and ankle.

Wright Medical Group NV was founded in the 1940s by René Tornier in Saint-Ismier, France. The Company is a medical device company focused on extremities and biologics products. It provides surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets. The Company has operations located in Memphis, Tennessee (U.S. headquarters, research and development, sales and marketing administration, and administrative activities); Bloomington, Minnesota (upper extremities sales and marketing); Arlington, Tennessee (manufacturing and warehousing operations); Grenoble, France (manufacturing and research and development); and Macroom, Ireland (manufacturing). In addition, it has local sales and distribution offices in Canada, Australia, Asia, and throughout Europe. The Company operates in one segment, orthopaedic products, which includes the design, manufacture, marketing, and sales of extremities and biologics products. It offers product portfolio of over 160 extremities products and 20 biologics products that are designed to provide solutions to its surgeon customers. Its product portfolio consists of Upper extremities, which include joint implants and bone fixation devices for the shoulder, elbow, wrist, and hand; Lower extremities, which include joint implants and bone fixation devices for the foot and ankle; Biologics, which include products used to support treatment of damaged or diseased bone, tendons, and soft tissues or to stimulate bone growth; Sports medicine and other, which include products used across several anatomic sites to mechanically repair tissue-to-tissue or tissue-to-bone injuries and other ancillary products; and Large joints, which include hip and knee replacement implants. Its sales and marketing efforts are engaged in orthopaedic, trauma, and podiatric surgeons. The Company's sales and distribution system in the United States consisted of 65 geographic sales territories that are staffed by 458 direct sales representatives and 30 independent sales agencies or distributors. Internationally, it sells its full product portfolio, including products for upper and lower extremities, biologics, sports medicine and other, and large joints. Its international sales and distribution system currently consists of 11 direct sales offices and approximately 90 distributors that sell products in over 50 countries. It has subsidiaries with direct sales offices in the United Kingdom, France, Germany, Italy, Denmark, Netherlands, Canada, Japan, and Australia. Its products are sold in other countries in Europe, Asia, Africa, and Latin America using stocking distribution partners. The Company manufactures its internally-sourced products in four locations: Arlington, Tennessee; Montbonnot, France; Grenoble, France; and Macroom, Ireland. It leases the manufacturing facility in Arlington, Tennessee from the Industrial Development Board of the Town of Arlington. The Com

Ratios

vs
industry
vs
history
P/B 3.02
TRNX's P/B is ranked lower than
52% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.93 vs. TRNX: 3.02 )
Ranked among companies with meaningful P/B only.
TRNX' s P/B Range Over the Past 10 Years
Min: 1.47  Med: 2.01 Max: 4.84
Current: 3.02
1.47
4.84
P/S 3.27
TRNX's P/S is ranked higher than
50% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 3.21 vs. TRNX: 3.27 )
Ranked among companies with meaningful P/S only.
TRNX' s P/S Range Over the Past 10 Years
Min: 2.17  Med: 3.14 Max: 5.08
Current: 3.27
2.17
5.08
Current Ratio 1.96
TRNX's Current Ratio is ranked lower than
65% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. TRNX: 1.96 )
Ranked among companies with meaningful Current Ratio only.
TRNX' s Current Ratio Range Over the Past 10 Years
Min: 1.96  Med: 2.66 Max: 3.29
Current: 1.96
1.96
3.29
Quick Ratio 1.51
TRNX's Quick Ratio is ranked lower than
62% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. TRNX: 1.51 )
Ranked among companies with meaningful Quick Ratio only.
TRNX' s Quick Ratio Range Over the Past 10 Years
Min: 1.18  Med: 1.6 Max: 1.99
Current: 1.51
1.18
1.99
Days Inventory 319.61
TRNX's Days Inventory is ranked lower than
86% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 133.25 vs. TRNX: 319.61 )
Ranked among companies with meaningful Days Inventory only.
TRNX' s Days Inventory Range Over the Past 10 Years
Min: 319.61  Med: 432.62 Max: 530.83
Current: 319.61
319.61
530.83
Days Sales Outstanding 76.78
TRNX's Days Sales Outstanding is ranked lower than
57% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 68.90 vs. TRNX: 76.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
TRNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.15  Med: 72.28 Max: 115.13
Current: 76.78
64.15
115.13
Days Payable 56.39
TRNX's Days Payable is ranked lower than
51% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. TRNX: 56.39 )
Ranked among companies with meaningful Days Payable only.
TRNX' s Days Payable Range Over the Past 10 Years
Min: 51.36  Med: 84.7 Max: 156.08
Current: 56.39
51.36
156.08

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -35.00
TRNX's 3-Year Average Share Buyback Ratio is ranked lower than
89% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. TRNX: -35.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TRNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -35  Med: -19.6 Max: -7.6
Current: -35
-35
-7.6

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.04
TRNX's Price/Median PS Value is ranked higher than
50% of the 260 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. TRNX: 1.04 )
Ranked among companies with meaningful Price/Median PS Value only.
TRNX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.71  Med: 1.06 Max: 1.46
Current: 1.04
0.71
1.46
Earnings Yield (Greenblatt) (%) -8.10
TRNX's Earnings Yield (Greenblatt) (%) is ranked lower than
69% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. TRNX: -8.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TRNX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -9.2  Med: 0 Max: 0
Current: -8.1
-9.2
0

More Statistics

Short Percentage of Float6.00%
52-Week Range $20.25 - 28.53
Shares Outstanding (Mil)49.27
» More Articles for TRNX

Headlines

Articles On GuruFocus.com
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Jul 29 2016 
John Keeley Comments on Wright Medical Group Apr 26 2016 

More From Other Websites
Here is What Hedge Funds Think About California Resources Corporation. (CRC) Nov 28 2015
WRIGHT MEDICAL GROUP N.V. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Nov 27 2015
Should You Avoid Wright Medical Group NV (TRNX)? Nov 25 2015
Tornier reports 3Q loss Nov 04 2015
WRIGHT MEDICAL GROUP N.V. Files SEC form 8-K, Change in Directors or Principal Officers, Amendment... Oct 16 2015
WRIGHT MEDICAL GROUP N.V. Financials Oct 07 2015
WRIGHT MEDICAL GROUP N.V. Files SEC form 8-K, Termination of a Material Definitive Agreement,... Oct 01 2015
Wright Medical, Tornier Merger Receives FTC Approval Oct 01 2015
Wright Medical completes Tornier merger Oct 01 2015
Tornier NV Earnings Q2, 2015 Oct 01 2015
Wright Medical Group, Tornier win U.S. approval to merge Sep 30 2015
EndoChoice® Announces Bill Enquist and Dave Mowry Join Board of Directors Sep 09 2015
Integra LifeSciences to Acquire Total Ankle Replacement (Salto Talaris(R)) and Silastic Toe... Sep 03 2015
TORNIER N.V. Files SEC form 8-K, Other Events, Regulation FD Disclosure, Financial Statements and... Sep 03 2015
Integra LifeSciences to Acquire Total Ankle Replacement (Salto Talaris(R)) and Silastic Toe... Sep 03 2015
Tornier reports 2Q loss Aug 05 2015
TORNIER N.V. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 05 2015
Tornier reports 1Q loss May 05 2015
Tornier reports 4Q loss Feb 24 2015
Tornier misses 3Q profit forecasts Nov 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)